Topics

BACEless: Eisai, Biogen Pull Plug on Alzheimer’s Drug in Final Stage

12:29 EDT 13 Sep 2019 | Xconomy

Add another once-promising Alzheimer’s disease drug to the scrap heap. Eisai and Biogen (NASDAQ: BIIB) are halting a Phase 3 test after an independent safety review concluded the risks of experimental Alzheimer’s drug elenbecestat outweigh the benefits. The companies did not explain what the independent board found. Some drugs that work the same way have […]

Original Article: BACEless: Eisai, Biogen Pull Plug on Alzheimer’s Drug in Final Stage

NEXT ARTICLE

More From BioPortfolio on "BACEless: Eisai, Biogen Pull Plug on Alzheimer’s Drug in Final Stage"

Quick Search

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...